Core Viewpoint - The company has received approval for the registration of Banxia Xiexin Decoction Granules, which will enhance its product portfolio in traditional Chinese medicine [1][4]. Group 1: Drug Information - The drug is named Banxia Xiexin Decoction Granules, in granule form, with a specification equivalent to 27.77g of herbal slices per bag [1]. - It is classified as a Category 3.1 traditional Chinese medicine, based on ancient classic prescriptions [1]. - The drug's approval number is Guoyao Zhunzi C20250017, and it is produced by Shanxi Guangyuyuan National Medicine Co., Ltd [1]. Group 2: Market Context - The prescription for Banxia Xiexin Decoction Granules originates from Zhang Zhongjing's "Shanghan Lun" and is included in the first batch of the National Administration of Traditional Chinese Medicine's classic formula directory [2]. - The market for gastrointestinal traditional Chinese medicine, including this product, is projected to reach a total sales amount of 10.615 billion yuan in 2024, reflecting a year-on-year increase of 1.01% [2]. - Currently, no other companies have obtained the drug registration certificate for Banxia Xiexin Decoction Granules in China [2]. Group 3: Company Investment - The company has invested a total of 9.0266 million yuan in the research and development of this drug to date [3]. Group 4: Impact on the Company - The approval of Banxia Xiexin Decoction Granules will diversify the company's traditional Chinese medicine product offerings and create synergies with existing core products [4].